Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Glatirameracetat injection solution in a prefilled syringe

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 461 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Injektionslösung in einer Fertigspritze, ATC L03AX13

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The buyer explicitly states this is an open-house model and not a normal open procedure; procurement-law remedies and c...

Contract documents must be submitted via the communication area, not the offer area; paper originals must be in duplica...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for Glatirameracetat in the form of injection solution in a prefilled syringe, ATC L03AX13.
  • Supply of pharmaceutical products under identical, pre-set contract terms.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical rebate agreement for Glatirameracetat injection solution in a prefilled syringe (ATC L03AX13) offered by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 01.02.2026 to 31.01.2028, with accession possible until 03.12.2027. Submission is either by handwritten originals in duplicate or electronically with a qualified electronic signature via DTVP. No contract value is provided.

Ryzyka

The buyer explicitly states this is an open-house model and not a normal open procedure; procurement-law remedies and c...

Contract documents must be submitted via the communication area, not the offer area; paper originals must be in duplica...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The contract must be completed and signed, together with the annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Glatirameracetat injection solution in a prefilled syringe

Single lot covering non-exclusive open-house rebate agreements for the medicinal product Glatirameracetat in injection solution in a prefilled syringe, ATC L03AX13. The lot is for supplies and appears to be a framework/open-house arrangement with no negotiated individual terms. The lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Jan 2026 - Jan 2028

Kategoria

Pharmaceutical products

Termin

Deadline Dec 03, 2027

Szczegóły zamówienia

Data publikacji
14 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
830560-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30